Starpharma (OTCMKTS:SPHRY) Stock Price Down 8.4% - What's Next?

Key Points

• Starpharma Holdings Ltd. saw its stock price decrease by 8.4%, closing the day at $1.75, down from a previous close of $1.91.
• Trading volume was significantly lower, with approximately 700 shares changing hands, marking a decline of 78% from its average daily volume of 3,178 shares.
• The company operates in the biopharmaceutical sector, focusing on the development of dendrimer products such as VivaGel BV and VIRALEZE for various health applications.

Starpharma Holdings Ltd. (OTCMKTS:SPHRY - ) was down 8.4% during mid-day trading on Friday . The company traded as low as $1.75 and last traded at $1.75. Approximately 700 shares traded hands during mid-day trading, a decline of 78% from the average daily volume of 3,178 shares. The stock had previously closed at $1.91.

Starpharma Stock Down 8.4%

The firm's fifty day simple moving average is $1.22 and its 200 day simple moving average is $0.82. The company has a current ratio of 4.32, a quick ratio of 3.95 and a debt-to-equity ratio of 0.06.

Starpharma Company Profile

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.